Nitric oxide suppresses EPO-induced monocyte chemoattractant protein-1 in endothelial cells: Implications for atherogenesis in chronic renal disease

Laboratory Investigation

Volumn 86, Issue 4, 2006, Pages 369-379

  Desai, Anjali ^a   Zhao, Ying ^a   Lankford, Heather A ^a   Warren, Jeffrey S ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

Chronic renal disease; Endothelial cells; Erythropoietin; Monocyte chemoattractant protein 1; Nitric oxide

Indexed keywords

CYTOKINE; ENDOTHELIAL NITRIC OXIDE SYNTHASE; MESSENGER RNA; MONOCYTE CHEMOTACTIC PROTEIN 1; NITRIC OXIDE; NITRIC OXIDE DONOR; RECOMBINANT ERYTHROPOIETIN;

ARTICLE; ATHEROGENESIS; ATHEROSCLEROSIS; CELL PROLIFERATION; CELL STIMULATION; CHRONIC KIDNEY DISEASE; CONTROLLED STUDY; DOWN REGULATION; ENDOTHELIUM CELL; ENZYME ACTIVITY; ENZYME INHIBITION; GENE EXPRESSION REGULATION; HUMAN; HUMAN CELL; IN VITRO STUDY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN INDUCTION; RNA ANALYSIS; SMOOTH MUSCLE FIBER; UMBILICAL VEIN; VASCULAR ENDOTHELIUM; VASCULAR SMOOTH MUSCLE;

ATHEROSCLEROSIS; CELL PROLIFERATION; CELLS, CULTURED; CHEMOKINE CCL2; DOWN-REGULATION; ENDOTHELIAL CELLS; ENDOTHELIUM, VASCULAR; ERYTHROPOIETIN, RECOMBINANT; HUMANS; KIDNEY FAILURE, CHRONIC; MYOCYTES, SMOOTH MUSCLE; NF-KAPPA B; NITRIC OXIDE; RNA, MESSENGER;

EID: 33645323500     PISSN: 00236837     EISSN: 15300307     Source Type: Journal    
DOI: 10.1038/labinvest.3700396     Document Type: Article

References (48)

1. London GM, Drueke TB. Atherosclerosis and arteriosclerosis in chronic renal failure. Kidney Int 1997;51:1678-1695.
2. Stenvinkel P, O Heimbürger O Paultre F. Strong association between malnutrition inflammation and atherosclerosis in chronic renal failure. Kidney Int 1999;55:1899-1911.
3. Morris ST, Jardine AG. The vascular endothelium in chronic renal failure. J Nephrol 2000;13:96-105.
4. Adamson JW, Eschbach JW. Erythropoietin for end-stage renal disease. N Engl J Med 1998;339:625.
5. Vaziri ND. Mechanism of Erythropoietin-induced hypertension. Am J Kidney Dis 1999;33:821-827.
6. Haller H, Christel C, Dannenberg L, et al. Signal transduction of erythropoietin in endothelial cells. Kidney Int 1996;50:481-488.
7. Gewaltig MT, Kojda G. Vasoprotection by nitric oxide: mechanisms and therapeutic potential. Cardiovasc Res 2002;55:250-260.
8. Wang XQ, Vaziri ND. Erythropoietin depresses nitric oxide synthese expression by endothelial cells. Hypertension 1999;33:894-899.
9. Terkeltaub R, Boisvert WA, Curtiss LK. Chemokines and atherosclerosis. Curr Opin Lipidol 1998;19:387-405.
10. Aiello RJ, Bourassa P-A K, Lindsey SL. Monocyte chemoattractant protein-1 accelerates atherosclerosis in apolipoprotein E-deficient mice. Arterioscler Thromb Vasc Biol 1999;19:1518-1525.
11. Napoli C, Ignarro LJ. Nitric oxide and atherosclerosis. Nitric oxide: Biol Chem 2001;5:88-97.
12. Gauthier TW, Scalia R, Murohara T, et al. Nitric oxide protects against leukocyte-endothelium interactions in the early stages of hypercholesterolemia. Arterioscler Thromb Vasc Biol 1995;15:1652-1659.
13. De Graaf JC, Banga JD, Moncada S, et al. Nitric oxide functions as an inhibitor of platelet adhesion under flow conditions. Circulation 1992;85:2284-2290.
14. Draijer R, Atsma DE, van der Laarse A, et al. CGMP and nitric oxide modulate thrombin-induced endothelial permeability: regulation via different pathways in human aortic and umbilical vein endothelial cells. Circ Res 1995;76:199-208.
15. Cardona-Sanclemente LE, Born GV. Effect of inhibition of nitric oxide synthesis on the uptake of LDL and fibrinogen by arterial walls and other organs of the rat. Br J Pharmacol 1995;114:1490-1494.
16. Rikitake Y, Hirata K, Kawashima S, et al. Inhibitory effect of inducible type nitric oxide synthase on oxidative modification of low density lipoprotein by vascular smooth muscle cells. Atherosclerosis 1998;136:51-57.
17. Dubey RK, Jackson EK, Luscher TF. Nitric oxide inhibits angiotension II-induced migration of rat smooth muscle cells. Atherosclerosis 1995;136:51-57.
18. Garg YC, Hassid A. Nitric oxide-generating vasodilators and 8-bromocyclic guanosine monophosphate inhibit mitogenesis and proliferation of cultured rat vascular smooth muscle cells. J Clin Invest 1989;83:1774-1777.
19. Del Castillo D, Raij L, Shultz PJ, et al. The pressor effect of recombinant human erythropoietin is not due to decreased activity of the endogenous nitric oxide system. Nephrol Dial Transplant 1995;10:505-508.
20. Tsukahara H, Hiraoka M, Hori C. Chronic erythropoietin treatment enhances endogenous nitric oxide production in rats. Scand J Clin Lab Invest 1997;57:487-494.
21. Kanagy NL, Perrine MF, Cheung DK, et al. Erythropoietin administration in vivo increases vascular nitric oxide synthase expression. J Cardiovasc Pharmacol 2003;42:4.
22. Wu XC, Johns EJ, Richards NT. Relationship between erythropoietin and nitric oxide in the contraction of renal arcuate arteries and human umbilical vein endothelial cells. Clin Sci 1999;97:413-419.
23. Vaziri ND, Zhou XJ, Naqvi F. Role of nitric oxide resistance in erythropoietin-induced hypertension in rats with chronic renal failure. Am J Physiol 1996;271:E113-E122.
24. Schmidt RJ, Baylis C. Total nitric oxide production is low in patients with chronic renal disease. Kidney Int 2000;58:1261-1266.
25. Desai A, Miller MJ, Gomez HF, et al. Loxosceles deserta venom induces NF-κB-dependent chemokine production by endothelial cells. Clin Toxicol 1999;37:447-456.
26. Martin TM, Cardarelli PM, Parry GCN, et al. Cytokine induction of monocyte chemoattractant protein-1 gene expression in human endothelial cells depends on the cooperative action of NF-κ and AP-1. Eur J Immunol 1997;27:1091-1097.
27. Roebuck KA, Carpenter LR, Lakshminarayanan V. Stimulus-specific regulation of chemokine expression involves differential activation of the redox-sensitive transcription factors AP-1 and NF-κB. J Leukoc Biol 1999;65:291-298.
28. Ihling C, Haendeler JG. Co-expression of p53 and MDM2 in human atherosclerosis: implications for the regulation of cellularity of atherosclerotic lesions. J Pathol 1998;185:303-312.
29. Eckart K. After 15 years of success-perspectives of erythropoietin therapy. Nephrol Dial Transplant 2001;16:1745-1749.
30. Buckner FS, Eschbach JW, Haley NR, et al. Hypertension following erythropoietin therapy in anemic hemodialysis patients. AmJ Hypertens 1990;3:947-955.
31. Banerjee D, Rodriguez M, Nag M, et al. Exposure of endothelial cells to recombinant human erythropoietin induces nitric oxide synthase activity. Kidney Int 2000;57:1895-1904.
32. Bevilacqua A, Ceriani MC, Capaccioli S, et al. Post-transriptional regulation of gene expression by degradation of messenger RNAs. J Cell Physiol 2003;195:356-372.
33. Brueckmann M, Marx A, Weiler HM, et al. Stabilization of monocyte chemoattractant protein-1-mRNA by activated protein C. Thromb Haemost 2003;89:149-160.
34. Vogel Kramer HJ, Backer A. Effects of erythropoietin on endothelin-1 synthesis and the cellular calcium messenger system in vascular endothelial cells. Am J Hypertens 1997;10:289-296.
35. Neusser M, Tepel M, Zidek W. Erythropoietin increases cytosolic free calcium concentration in vascular smooth muscle cells. Cardiovasc Res 1993;27:1233-1236.
36. Anagnostou A, Lee ES, Kessimian N, et al. Erythropoietin has a mitogenic and positive chemotactic effect on endothelial cells. Proc Natl Acad Sci USA 1990;87:5978-5982.
37. Akimoto T, Kusano E, Muto S. The effect of erythropoietin on interleukin-1β mediated increase in nitric oxide synthesis in vascular smooth muscel cells. J Hypertens 1999;17:1249-1256.
38. Bieber E. Erythropoietin the biology of erythropoiesis and epoetin alfa. An overview. J Reprod Med 2001;46:521-530.
39. Kusano E, Akimoto T, Inoue M, et al. Human recombinant erythropoietin inhibits interleukin-1b-stimulated nitric oxide and cyclic guanosine monophosphate production in cultured rat vascular smooth-muscle cells. Nephrol Dial Transplant 1999;14:597-603.
40. Nielsen OJ. Pharmacokinetics of recombinant human erythropoietin in chronic haemodialysis patients. Pharmacol Toxicol 1990;66:83-86.
41. Hojs R. Carotid intima-media thickness and plaques in hemodialysis patients. Artif Organs 2000;24:691-695.
42. Vaziri ND, Ni Z, Wang XQ, et al. Downregulation of nitric oxide synthase in chronic renal insufficiency: role of excess PTH. Am J Physiol 1998;274:F642-F649.
43. Ni Z, Wang XQ, Vaziri ND. Nitric oxide metabolism in erythropoietin- induced hypertension. Effects of calcium channel blockade. Hypertension 1998;32:724-729.
44. De Marchi S, Cecchin E, Faletti E, et al. Long-term effects of erythropoietin therapy on fistula stenosis and plasma concentrations of PDGF and MCP-1 in hemodialysis patients. J Am Soc Nephrol 1997;8:1147-1156.
45. Papayianni A, Alexopoulos E, Gaimalis P, et al. Circulating levels of ICAM-1 VCAM-1 and MCP-1 are increased in haemodialysis patients: association with inflammation dyslipidaemia and vascular events. Nephrol Dial Transplant 2002;17:435-441.
46. Morena M, Cristol JP, Canaud B. Why hemodialysis patients are in a prooxidant state? What could be done to correct the pro/antioxidant imbalance. Blood Purification 2000;18:191-199.
47. Nourooz-Zadeh J. Effect of dialysis on oxidative stress in uraemia. Redox Rep 1999;14:17-22.
48. Tous M, Ferre N, Vilella E, et al. Circulating blood cells modulate the atherosclerotic process in apolipoprotein E-deficient mice. Metabolism 2004;53:95-100.